Late Stent Recoil of the Bioabsorbable Everolimus-Eluting Coronary Stent and its Relationship With Plaque Morphology — Shuzou Tanimoto (2008) | RDL Network
Late Stent Recoil of the Bioabsorbable Everolimus-Eluting Coronary Stent and its Relationship With Plaque Morphology
Journal of the American College of Cardiology 52(20): 1616-1620
Article 2008 English
Authors
ST
Shuzou Tanimoto
NB
Nico Bruining
RD
Ron T. van Domburg
Abstract
1 min read
Objectives
This study sought to evaluate late recoil of a novel bioabsorbable everolimus-eluting coronary stent (BVS), which is composed of a poly-L-lactic acid backbone, coated with a bioabsorbable polymer containing everolimus.
Background
Little is known about the mechanical behavior of bioabsorbable polymer stents after deployment in diseased human coronary arteries.
Methods
The study population consisted of 16 patients, who were treated with elective BVS implantation for single de novo native coronary artery lesions and were followed at 6 months. All patients underwent an intravascular ultrasound examination at post-procedure and follow-up. A total of 484 paired cross-sectional areas (CSAs) were acquired and analyzed. Late absolute stent recoil was defined as stent area at post-procedure (X) − stent area at follow-up (Y). Late percent stent recoil was defined as (X − Y)/X × 100. In each CSA, plaque morphology was assessed qualitatively and classified as calcific, fibronecrotic, or fibrocellular plaque.
Results
Late absolute and percent recoil of the BVS was 0.65 ± 1.71 mm2 (95% confidence interval [CI]: 0.49 to 0.80 mm2) and 7.60 ± 23.3% (95% CI: 5.52% to 9.68%). Calcified plaques resulted in significantly less late recoil (0.20 ± 1.54 mm2 and 1.97 ± 22.2%) than fibronecrotic plaques (1.03 ± 2.12 mm2 and 12.4 ± 28.0%, p = 0.001 and p = 0.001, respectively) or fibrocellular plaque (0.74 ± 1.48 mm2 and 8.90 ± 19.8%, p = 0.001 and p = 0.001, respectively).
Conclusions
The BVS shrank in size during the follow-up period. The lesion morphology of stented segments might affect the degree of late recoil of the BVS. (ABSORB Everolimus Eluting Coronary Stent System First in Man Clinical Investigation; NCT00300131)
Yoshinobu Onuma, Patrick W. Serruys, J.A. Fernández Gómez, Bernard De Bruyne, Dariusz Dudek, Leif Thuesen, Peter Smits, Bernard Chevalier, Dougal McClean, Jacques Koolen, Stephan Windecker, Robert Whitbourn, Ian T. Meredith, Héctor M. García‐García, John A. Ormiston
John A. Ormiston, Patrick W. Serruys, Evelyn Regar, Dariusz Dudek, Leif Thuesen, Mark Webster, Yoshinobu Onuma, Héctor M. García‐García, Robert McGreevy, Susan Veldhof
Nico Bruining, Sebastiaan de Winter, Jos R.T.C. Roelandt, Evelyn Regar, Iddo Heller, Ron T. van Domburg, Ronald Hamers, Yoshinobu Onuma, Darius Dudek, Mark Webster, Leif Thuesen, John A. Ormiston, Wai‐Fung Cheong, Karine Miquel‐Hébert, Susan Veldhof, Patrick W. Serruys
Patrick W. Serruys, John A. Ormiston, Yoshinobu Onuma, Evelyn Regar, Nieves Gonzalo, Héctor M. García‐García, Koen Nieman, Nico Bruining, Cécile Dorange, Karine Miquel‐Hébert, Susan Veldhof, Mark Webster, Leif Thuesen, Dariusz Dudek
Discussion(0)
No comments yet. Be the first to comment.